FDA Alerts

The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.

The US Food and Drug Administration recently announced approval of nivolumab as an adjuvant treatment for eligible patients with stage IIB or IIC completely resected melanoma.

The US Food and Drug Administration recently announced approval of VYJUVEK (beremagene geperpavec [B-VEC]) for the treatment of wounds in patients ages 6 months and older with dystrophic epidermolysis bullosa.

The US Food and Drug Administration recently announced approval of dupilumab as the first and only treatment indicated for adults with prurigo nodularis.

The US Food and Drug Administration recently announced approval of baricitinib oral tablets to treat adult patients with severe alopecia areata.